country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-101950

Copy Link Print Information

KIN1148

4 Cited Publications

Avis client

Based on 4 publication(s) in Google Scholar

KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 98.0%
CAS No.: 1428729-56-9
Formule: C₁₉H₁₁N₃OS₂
Masse moléculaire:361.44

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

KIN1148 Chemical Structure

CAS No.: 1428729-56-9

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvant et solubilité
- In Vitro
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

KIN1148, a small-molecule IRF3 agonist, is a novel influenza vaccine adjuvant found to enhance flu vaccine efficacy.

In Vitro

KIN1148 induces the dose-dependent nuclear translocation of IRF3 in PH5CH8 cells and specific activation of IRF3- responsive promoters. KIN1148 also elicits greater induction of endogenous IRF3-dependent ISG54 and OASL expression by PH5CH8 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Prime-boost immunization of mice with a suboptimal dose of a monovalent pandemic influenza split virus H1N1 A/California/07/2009 vaccine plus KIN1148 protect against a lethal challenge with mouse-adapted influenza virus (A/California/04/2009) and induce an influenza virusspecific IL-10 and Th2 response by T cells derived from lung and lung-draining lymph nodes. Primeboost immunization with vaccine plus KIN1148, but not prime immunization alone, induce antibodies capable of inhibiting influenza virus hemagglutinin and neutralizing viral infectivity. Nevertheless, a single immunization with vaccine plus KIN1148 provide increased protection over vaccine alone and reduce viral load in the lungs after challenge^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1428729-56-9
Appearance Solid
Masse moléculaire 361.44
Formule C₁₉H₁₁N₃OS₂
Color Light yellow to yellow
SMILES

O=C(NC1=NC2=CC=C3C(N=CS3)=C2S1)C4=CC5=C(C=C4)C=CC=C5
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All WB

Sort by:

Journal Impact Factor

Immunity

Mitochondrial DNA released by senescent tumor cells enhances PMN-MDSC-driven immunosuppression through the cGAS-STING pathway. [Abstract]

2025 Apr 8;58(4):811-825.e7. PMID: 40203808
Cell Commun Signal

EBV (LMP1) enhances cisplatin resistance by enhancing degradation of interferon regulatory factor 3. [Abstract]

2026 May 15;24(1):395. PMID: 42141449
Int Immunopharmacol

4-octyl itaconate ameliorates alveolar macrophage pyroptosis against ARDS via rescuing mitochondrial dysfunction and suppressing the cGAS/STING pathway. [Abstract]

2023 May:118:110104. PMID: 37004345

KIN1148 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 May:118:110104. [Abstract]

KIN1148 (10 μM) significantly increases the expressions of NLRP3, GSDMD-NT, and CASP-1 p20 while partially abolishes the inhibitory effect of 4-OI (4-octyl itaconate) on MH-S cells.
PLoS Negl Trop Dis

TBK1 and IRF3 are potential therapeutic targets in Enterovirus A71-associated diseases. [Abstract]

2023 Jan 10;17(1):e0011001. PMID: 36626364

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (276.67 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7667 mL

13.8336 mL

27.6671 mL

5 mM

0.5533 mL

2.7667 mL

5.5334 mL

10 mM

0.2767 mL

1.3834 mL

2.7667 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Protocole

Animal Administration^[1]

Mice: The final liposomes prior to mixing with vaccine contained KIN1148 (5 mg/mL) and phospholipids (40 mg/mL) and are delivered intramuscularly (KIN1148 at 50 μg and phospholipid at 400 μg per dose). Blank liposomes are prepared without KIN1148 as vehicle control. KIN1148 liposome and blank liposome formulations are stable for at least 4 months at 4°C and are used for in vivo experiments within a month after preparation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Probst P, et al. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response. Vaccine. 2017 Apr 4;35(15):1964-1971. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7667 mL	13.8336 mL	27.6671 mL	69.1678 mL
	5 mM	0.5533 mL	2.7667 mL	5.5334 mL	13.8336 mL
	10 mM	0.2767 mL	1.3834 mL	2.7667 mL	6.9168 mL
	15 mM	0.1844 mL	0.9222 mL	1.8445 mL	4.6112 mL
	20 mM	0.1383 mL	0.6917 mL	1.3834 mL	3.4584 mL
	25 mM	0.1107 mL	0.5533 mL	1.1067 mL	2.7667 mL
	30 mM	0.0922 mL	0.4611 mL	0.9222 mL	2.3056 mL
	40 mM	0.0692 mL	0.3458 mL	0.6917 mL	1.7292 mL
	50 mM	0.0553 mL	0.2767 mL	0.5533 mL	1.3834 mL
	60 mM	0.0461 mL	0.2306 mL	0.4611 mL	1.1528 mL
	80 mM	0.0346 mL	0.1729 mL	0.3458 mL	0.8646 mL
	100 mM	0.0277 mL	0.1383 mL	0.2767 mL	0.6917 mL

Keywords

KIN1148

4 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

MOQ

Minimum order quantity

100 mg

Obtenir un devis En stock

Other size

Obtenir un devis

Amount: USD 0.00

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvant et solubilité
- In Vitro
Protocole
Pureté et documentation
Références

1/16
1/16

KIN1148 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 May:118:110104. [Abstract]

Customer Validation
KIN1148 (10 μM) significantly increases the expressions of NLRP3, GSDMD-NT, and CASP-1 p20 while partially abolishes the inhibitory effect of 4-OI (4-octyl itaconate) on MH-S cells.

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

KIN1148

Anti-Infection Compound Library

Antiviral Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Heterocyclic Compound Library

Immunopotentiator Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) KIN1148

Activité biologique

Chemical Information

Publications (4)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

KIN1148

Anti-Infection Compound Library

Antiviral Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Heterocyclic Compound Library

Immunopotentiator Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) KIN1148

Activité biologique

Chemical Information

Publications (4)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

KIN1148 Related Classifications

HY-101950 Related Classifications